The contracted supplier of Abacavir (ABC) 600mg/Lamivudine (3TC} 300mg and Zidovudine (AZT) 300mg/3TC 150mg dual formulation tablets is unable to meet its contractual obligation due to an ongoing global shortage of 3TC, which has resulted in supply challenges. The contracted supplier is acquiring limited supplies of these agents using alternative methods. However, due to the current supply constraints, rational use of these medicines and appropriate monitoring is recommended by all provinces and health care facilities until the supply is fully restored. This may include implementing measures such as the redistribution of stock to facilities in need or the provision of a lower quantity of stock than usual to the patient e.g. issuing only a month's supply at a time. In case of complete stock out of ABC 600mg/3TC 300mg and AZT 300mg/3TC 150mg dual formulation tablets available at a facility, the recommended therapeutic alternative is Tenofovir (TDF) 300mg/Emtricitabine (FTC) 200mg dual formulation tablet, with the following caveats: